GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

FEED · Mar 31, 2023

ENvue Medical, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001493152-23-017233General Corporate
Capex intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.28% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-338.98% · OPTIONAL · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

625.14% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.gross_margin

66.38% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.operating_margin

-298.02% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

15.54% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

18.93% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History16 statesHistory building
Sep 30, 20220/7 normalizedLevel 3Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/7 normalizedLevel 3Jun 30, 20230/7 normalizedLevel 3Sep 30, 20230/8 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/8 normalizedLevel 3Sep 30, 20247/8 normalizedLevel 3Dec 31, 20247/8 normalizedLevel 3Mar 31, 20256/8 normalizedLevel 3Jun 30, 20256/7 normalizedLevel 3Sep 30, 20257/7 normalizedLevel 3Dec 31, 20257/7 normalizedLevel 3Mar 31, 20267/7 normalizedLevel 3Jun 30, 20267/7 normalizedLevel 3
Period transition

What moved in the state?

Capex Intensity Decreased
Previous
0.40%
Current
0.28%
Delta
-0.12%
Cash Generation Increased
Previous
-935.51%
Current
-338.98%
Delta
596.52%
Inventory Pressure Increased
Previous
289.23%
Current
625.14%
Delta
335.91%
Margin Increased
Previous
22.21%
Current
66.38%
Delta
44.18%
Profitability Increased
Previous
-666.49%
Current
-298.02%
Delta
368.47%
R And D Intensity Decreased
Previous
37.63%
Current
15.54%
Delta
-22.10%
Sbc Intensity Decreased
Previous
47.07%
Current
18.93%
Delta
-28.15%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · FEED Fundamental State →Has State · ENvue Medical, Inc. →Transitioned To · FEED Fundamental State →Transitioned To · FEED CAPEX_INTENSITY_DECREASED →Transitioned To · FEED CASH_GENERATION_INCREASED →Transitioned To · FEED INVENTORY_PRESSURE_INCREASED →Transitioned To · FEED MARGIN_INCREASED →Transitioned To · FEED PROFITABILITY_INCREASED →Transitioned To · FEED R_AND_D_INTENSITY_DECREASED →Transitioned To · FEED SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.